MDT

100.58

-1.14%↓

A

134.59

-3.4%↓

VEEV

221.73

-1.03%↓

HQY

84.73

-2.01%↓

NEOG

9.73

-2.41%↓

MDT

100.58

-1.14%↓

A

134.59

-3.4%↓

VEEV

221.73

-1.03%↓

HQY

84.73

-2.01%↓

NEOG

9.73

-2.41%↓

MDT

100.58

-1.14%↓

A

134.59

-3.4%↓

VEEV

221.73

-1.03%↓

HQY

84.73

-2.01%↓

NEOG

9.73

-2.41%↓

MDT

100.58

-1.14%↓

A

134.59

-3.4%↓

VEEV

221.73

-1.03%↓

HQY

84.73

-2.01%↓

NEOG

9.73

-2.41%↓

MDT

100.58

-1.14%↓

A

134.59

-3.4%↓

VEEV

221.73

-1.03%↓

HQY

84.73

-2.01%↓

NEOG

9.73

-2.41%↓

Search

CareDx Inc

Abierto

SectorSanidad

20.41 -2.86

Resumen

Variación precio

24h

Actual

Mínimo

20.28

Máximo

21.15

Métricas clave

By Trading Economics

Ingresos

10M

1.7M

Ventas

13M

100M

P/B

Media del Sector

15.633

89.037

Margen de beneficios

1.674

Empleados

644

EBITDA

11M

6.8M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

-13.59% downside

Dividendos

By Dow Jones

Próximas Ganancias

25 feb 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

279M

1.1B

Apertura anterior

23.27

Cierre anterior

20.41

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

174 / 360 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

CareDx Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

22 ene 2026, 21:55 UTC

Ganancias

Capital One Financial Posts Higher 4Q Profit As Lending Increases

22 ene 2026, 23:52 UTC

Ganancias

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- Update

22 ene 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Rise as Tensions Between U.S. and Europe Ease -- Market Talk

22 ene 2026, 23:42 UTC

Charlas de Mercado

Gold Edges Lower on Possible Profit-Taking -- Market Talk

22 ene 2026, 23:40 UTC

Charlas de Mercado

Spark NZ's Market Share Loss Concerns Bear -- Market Talk

22 ene 2026, 23:30 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

22 ene 2026, 23:30 UTC

Charlas de Mercado

Genesis Energy Can Beat Newly Upgraded Earnings Goal -- Market Talk

22 ene 2026, 22:37 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Capital One CEO: Brex Buy Reflects Business Payments Focus -- Market Talk

22 ene 2026, 21:59 UTC

Adquisiciones, fusiones, absorciones

Capital One Strikes $5.15 Billion Deal for Fintech Brex -- Update

22 ene 2026, 21:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

22 ene 2026, 21:44 UTC

Ganancias

Self-Driving Stock Mobileye Plunged After Earnings. Here's Why. -- Barrons.com

22 ene 2026, 21:32 UTC

Adquisiciones, fusiones, absorciones

Capital One: Brex Invented Integrated Combination of Corporate Credit Cards, Spend Management Software and Banking in Single Platform >COF

22 ene 2026, 21:31 UTC

Adquisiciones, fusiones, absorciones

Capital One: Brex Is a Modern, AI-native Software Platform Offering Intelligent Finance Solutions >COF

22 ene 2026, 21:31 UTC

Adquisiciones, fusiones, absorciones

Capital One: Franceschi Will Continue to Lead Brex as Part of Capital One >COF

22 ene 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

Capital One to Acquire Brex in Combination of Stk and Cash Transaction Valued at $5.15 B >COF

22 ene 2026, 21:30 UTC

Ganancias

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results -- WSJ

22 ene 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

Capital One To Acquire Brex >COF

22 ene 2026, 21:13 UTC

Ganancias

Intel Returns to Losses in Q4 as It Ramps Up Spending on Chip Production -- WSJ

22 ene 2026, 21:11 UTC

Ganancias

Intuitive Surgical Sees 2026 Impact From Tariffs 1.2% of Revenue, Plus or Minus 10 Basis Points >ISRG

22 ene 2026, 21:11 UTC

Ganancias

Intuitive Surgical Sees 2026 Adjusted Gross Profit Margin 67%-68% >ISRG

22 ene 2026, 21:10 UTC

Ganancias

Intuitive Surgical Sees 2026 Worldwide Da Vinci Procedure Growth of 13%-15% >ISRG

22 ene 2026, 21:06 UTC

Ganancias

Capital One 4Q Total Non-Interest Expense Increased 13% to $9.3B >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q Provision for Credit Losses Increased $4.1B >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q Rev $15.58B >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q EPS $3.26 >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q Net Interest Margin 8.26% >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q Net $2.13B >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q Adj EPS $3.86 >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q Net Charge-Offs $3.8B >COF

22 ene 2026, 21:05 UTC

Ganancias

Intuitive Surgical 4Q EPS $2.21 >ISRG

Comparación entre iguales

Cambio de precio

CareDx Inc previsión

Precio Objetivo

By TipRanks

-13.59% descenso

Estimación a 12 Meses

Media 18 USD  -13.59%

Máximo 18 USD

Mínimo 18 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CareDx Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

4 ratings

1

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

14.77 / 18.49Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

174 / 360 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.